134 related articles for article (PubMed ID: 10494234)
1. Hepatitis C: an economic evaluation of extended treatment with interferon.
Shiell A; Brown S; Farrell GC
Med J Aust; 1999 Aug; 171(4):189-93. PubMed ID: 10494234
[TBL] [Abstract][Full Text] [Related]
2. Assessing the cost-effectiveness of treating chronic hepatitis C virus in people who inject drugs in Australia.
Visconti AJ; Doyle JS; Weir A; Shiell AM; Hellard ME
J Gastroenterol Hepatol; 2013 Apr; 28(4):707-16. PubMed ID: 23173753
[TBL] [Abstract][Full Text] [Related]
3. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
Shepherd J; Jones J; Takeda A; Davidson P; Price A
Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
[TBL] [Abstract][Full Text] [Related]
4. Pretreatment evaluation of chronic hepatitis C: risks, benefits, and costs.
Wong JB; Bennett WG; Koff RS; Pauker SG
JAMA; 1998 Dec 23-30; 280(24):2088-93. PubMed ID: 9875876
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population.
Salomon JA; Weinstein MC; Hammitt JK; Goldie SJ
JAMA; 2003 Jul; 290(2):228-37. PubMed ID: 12851278
[TBL] [Abstract][Full Text] [Related]
6. Cost effectiveness of peginterferon alpha-2a plus ribavirin versus interferon alpha-2b plus ribavirin as initial therapy for treatment-naive chronic hepatitis C.
Sullivan SD; Craxi A; Alberti A; Giuliani G; De Carli C; Wintfeld N; Patel KK; Green J
Pharmacoeconomics; 2004; 22(4):257-65. PubMed ID: 14974875
[TBL] [Abstract][Full Text] [Related]
7. Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C.
Bennett WG; Inoue Y; Beck JR; Wong JB; Pauker SG; Davis GL
Ann Intern Med; 1997 Nov; 127(10):855-65. PubMed ID: 9382363
[TBL] [Abstract][Full Text] [Related]
8. Cost effectiveness of combination therapy for hepatitis C: a decision analytic model.
Stein K; Rosenberg W; Wong J
Gut; 2002 Feb; 50(2):253-8. PubMed ID: 11788569
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness and cost-utility of the treatment of chronic hepatitis B with peginterferon alfa-2a, interferon alfa, and lamivudine in Lithuania.
Vanagas G; Padaiga Z; Mickevičienė A
Medicina (Kaunas); 2010; 46(12):835-42. PubMed ID: 21532288
[TBL] [Abstract][Full Text] [Related]
10. Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation.
Shepherd J; Brodin H; Cave C; Waugh N; Price A; Gabbay J
Health Technol Assess; 2004 Oct; 8(39):iii-iv, 1-125. PubMed ID: 15461877
[TBL] [Abstract][Full Text] [Related]
11. Cost-Effectiveness Modelling of Sofosbuvir-Containing Regimens for Chronic Genotype 5 Hepatitis C Virus Infection in South Africa.
Fraser I; Burger J; Lubbe M; Dranitsaris G; Sonderup M; Stander T
Pharmacoeconomics; 2016 Apr; 34(4):403-17. PubMed ID: 26666639
[TBL] [Abstract][Full Text] [Related]
12. New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis.
Liu S; Cipriano LE; Holodniy M; Owens DK; Goldhaber-Fiebert JD
Ann Intern Med; 2012 Feb; 156(4):279-90. PubMed ID: 22351713
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analysis of antiviral treatment in liver transplant recipients with HCV infection.
Logge C; Vettorazzi E; Fischer L; Nashan B; Sterneck M
Transpl Int; 2013 May; 26(5):527-34. PubMed ID: 23517333
[TBL] [Abstract][Full Text] [Related]
14. Economic evaluation of pegylated interferon plus ribavirin for treatment of chronic hepatitis C in Thailand: genotype 1 and 6.
Kapol N; Lochid-Amnuay S; Teerawattananon Y
BMC Gastroenterol; 2016 Aug; 16(1):91. PubMed ID: 27492396
[TBL] [Abstract][Full Text] [Related]
15. Peginterferon alfa-2a versus peginterferon alfa-2b as initial treatment of hepatitis C virus infection: a cost-utility analysis from the perspective of the Veterans Affairs Health Care System.
Yeh WS; Armstrong EP; Skrepnek GH; Malone DC
Pharmacotherapy; 2007 Jun; 27(6):813-24. PubMed ID: 17542764
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of 6 and 12 months of interferon-alpha therapy for chronic hepatitis C.
Kim WR; Poterucha JJ; Hermans JE; Therneau TM; Dickson ER; Evans RW; Gross JB
Ann Intern Med; 1997 Nov; 127(10):866-74. PubMed ID: 9382364
[TBL] [Abstract][Full Text] [Related]
17. Treatment for hepatitis C virus in human immunodeficiency virus-infected patients: clinical benefits and cost-effectiveness.
Kuehne FC; Bethe U; Freedberg K; Goldie SJ
Arch Intern Med; 2002 Dec 9-23; 162(22):2545-56. PubMed ID: 12456226
[TBL] [Abstract][Full Text] [Related]
18. Cost Effectiveness of Early Treatment with Direct-Acting Antiviral Therapy in Adolescent Patients with Hepatitis C Virus Infection.
Nguyen J; Barritt AS; Jhaveri R
J Pediatr; 2019 Apr; 207():90-96. PubMed ID: 30738661
[TBL] [Abstract][Full Text] [Related]
19. Treatment of chronic hepatitis B with interferon-alpha: cost-effectiveness in developing countries.
Aggarwal R; Ghoshal UC; Naik SR
Natl Med J India; 2002; 15(6):320-7. PubMed ID: 12540064
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of interferon alfa-2b with and without ribavirin as therapy for chronic hepatitis C in Sweden.
Sennfält K; Reichard O; Hultkrantz R; Wong JB; Jonsson D
Scand J Gastroenterol; 2001 Aug; 36(8):870-6. PubMed ID: 11495084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
